The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC.

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets.

Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.

Does thermal biology differ between two colour pattern morphs of a widespread Australian lizard?

Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).

Multiligament stifle injury, a multicenter retrospective study in 26 dogs.

Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C).

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.

Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021.

Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis.